Coca-Cola Launches Global 'Recycle Me' Campaign to Champion Recycling 
TSMC to Hike Prices for Chips Made Outside Taiwan, Impacting Global Device Costs 
The Original Mouthful: McDonald's Australia Revives Legendary Big Mac Chant with a Tech Twist 
Tesla Dismisses 285 Buffalo, New York Workers in Restructuring Efforts 
Hyundai Halts Advertising on X Amid Antisemitism Row 
Samsung's Exynos 2500 Rumored to Eclipse Snapdragon 8 Gen 4 in Power Efficiency With 3nm SoC 
LVMH Adds Bernard Aranault’s Sons Frederic and Alexandre Arnault to the Board 
SPC Group’s Paris Baguette Inaugurates First Bakery Shop in the Philippines 
Lotte Wellfood Brings Its Pepero Products to Thailand’s King Power Duty-Free Shop 
Polestar to Launch Polestar 4 Pure EV in South Korea 
Nissan Cuts Profit Forecasts Amidst Sales Slump and Natural Disaster 
Taeyoung to Sack Executives, Cut Employees' Salaries to Save Company 
Samsung Implements Emergency 6-Day Work Week to Combat Slowing Growth 
5 Reasons Businesses Can’t Afford Not to Get Fleet Maintenance Software 
Google Fired Workers Protesting Over Cloud Contract Deal With Israel 
Starbucks Revamps Cups to Ease Plastic Waste; New Design to Roll Out in US, Canada 
ROCKVILLE, Md., Feb. 28, 2017 -- REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy based on its proprietary NAV® Technology Platform, today announced that it will host a conference call on Tuesday, March 7, 2017 at 4:30 p.m. ET to discuss its financial results for the quarter and full year ended December 31, 2016 and recent operational highlights.
To access the live call by phone, dial (855) 422-8964 (domestic) or (210) 229-8819 (international), and enter the passcode 77596619. To access a live or recorded webcast of the call, please visit the “Investors” section of the REGENXBIO website at www.regenxbio.com. The recorded webcast will be available for approximately 30 days following the call.
About REGENXBIO
REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. REGENXBIO’s NAV® Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO’s mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on REGENXBIO’s NAV Technology Platform. REGENXBIO seeks to accomplish this mission through a combination of internal development efforts and third-party NAV Technology Platform Licensees. REGENXBIO and its licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.
CONTACT: Investors Heather Savelle, 646-395-3734 [email protected] Media Laura Bagby, 312-448-8098 [email protected]
